The US Food and Drug Administration (FDA) has granted Fast Track Designation for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody in development for the...

AbbVie has announced that late-breaking results from the phase 2 IMGN853-0420 trial. The study evaluated the potential efficacy and safety of mirvetuximab soravtansine-gynx, a first-in-class antibody-drug...

Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, has announced that the first patient has been dosed in its...

Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, announced an upgrade of its manufacturing site in Geneva to...

Virica Biotech, a cell enhancer company specialising in Viral Sensitizers for viral vector manufacturing, has announced receipt of advisory services and funding from the...

Novartis has announced that it has entered into an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases....

Halozyme Therapeutics has announced its wholly-owned subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated. Under the collaboration,...

Biogen has announced that the high dose regimen of Spinraza® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, has been approved...